JAK2 and myeloproliferative disorder: Decreased expression or TPO-MPL function results in thrombocytopenia, whereas hyperactivation of MPL signalling (due to TPO receptor mutation or JAK2 mutation) results in myeloproliferative neoplasms (MPNs).